Fluoxetine inhibits corticotropin-releasing factor (CRF)-induced behavioural responses in rats
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Stress
- Vol. 12 (3) , 225-239
- https://doi.org/10.1080/10253890802309861
Abstract
Corticotropin-releasing factor (CRF) is a potent neuromodulator of stress-related behaviour but the neural mechanisms underlying these effects are not clear. Studies were designed to test the hypothesis that CRF-induced behavioural arousal involves interactions with brainstem serotonergic systems. To examine interactions between CRF and serotonergic systems in the regulation of behaviour, CRF (1 μg, intracerebroventricular (i.c.v.)) or vehicle was infused in the presence or absence of the selective serotonin re-uptake inhibitor fluoxetine (0, 0.1, 1 or 10 mg/kg, intravenous (i.v.)). Fluoxetine was used at these doses because it is known to decrease serotonin cell firing rates while increasing extracellular serotonin concentrations in select forebrain regions. We then measured behavioural, neurochemical and endocrine responses. CRF increased locomotion and spontaneous non-ambulatory motor activity (SNAMA) in the home cages. Fluoxetine decreased tissue 5-hydroxyindoleacetic acid concentrations, a measure of serotonin metabolism, in specific limbic brain regions of CRF-treated rats (nucleus accumbens shell region, entorhinal cortex, central nucleus of the amygdala). Furthermore, fluoxetine inhibited CRF-induced SNAMA. CRF and fluoxetine independently increased plasma corticosterone concentrations, but the responses had distinct temporal profiles. Overall, these data are consistent with the hypothesis that CRF-induced facilitation of behavioural activity is dependent on brainstem serotonergic systems. Therefore, fluoxetine may attenuate or alleviate some behavioural responses to stress by interfering with CRF-induced responses.Keywords
This publication has 103 references indexed in Scilit:
- Activation of Raphe Efferents to the Medial Prefrontal Cortex by Corticotropin-Releasing Factor: Correlation with Anxiety-Like BehaviorPublished by Elsevier ,2007
- Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphé differentially affect serotonin release in the nucleus accumbensEuropean Journal of Pharmacology, 2007
- Species and sex differences in brain distribution of corticotropin-releasing factor receptor subtypes 1 and 2 in monogamous and promiscuous vole speciesJournal of Comparative Neurology, 2005
- Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdalaNeuroscience, 2004
- Differential Distribution of Corticotropin-Releasing Hormone Immunoreactive Axons in Monoaminergic Nuclei of the Human BrainstemNeuropsychopharmacology, 1997
- Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Activating and ‘anxiogenic’ effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasoneLife Sciences, 1986
- Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRFLife Sciences, 1986
- Determination of monoamines in brain nuclei by high performance liquid chromatography with electrochemical detection : Young vs. middle aged ratsLife Sciences, 1984
- Extension of Sample Sizes and Percentage Points for Significance Tests of Outlying ObservationsTechnometrics, 1972